Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20586923rdf:typepubmed:Citationlld:pubmed
pubmed-article:20586923lifeskim:mentionsumls-concept:C0034656lld:lifeskim
pubmed-article:20586923lifeskim:mentionsumls-concept:C1522318lld:lifeskim
pubmed-article:20586923lifeskim:mentionsumls-concept:C0032176lld:lifeskim
pubmed-article:20586923lifeskim:mentionsumls-concept:C0021467lld:lifeskim
pubmed-article:20586923lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:20586923lifeskim:mentionsumls-concept:C0070166lld:lifeskim
pubmed-article:20586923lifeskim:mentionsumls-concept:C1707455lld:lifeskim
pubmed-article:20586923lifeskim:mentionsumls-concept:C0021469lld:lifeskim
pubmed-article:20586923lifeskim:mentionsumls-concept:C0040808lld:lifeskim
pubmed-article:20586923lifeskim:mentionsumls-concept:C2348535lld:lifeskim
pubmed-article:20586923lifeskim:mentionsumls-concept:C1511237lld:lifeskim
pubmed-article:20586923lifeskim:mentionsumls-concept:C1705509lld:lifeskim
pubmed-article:20586923lifeskim:mentionsumls-concept:C1550436lld:lifeskim
pubmed-article:20586923lifeskim:mentionsumls-concept:C2348480lld:lifeskim
pubmed-article:20586923pubmed:issue9lld:pubmed
pubmed-article:20586923pubmed:dateCreated2010-10-28lld:pubmed
pubmed-article:20586923pubmed:databankReferencehttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20586923pubmed:abstractTextOn top of aspirin, an abciximab bolus-only regimen results in a 30% drop in platelet inhibition at 6 h as compared with the on-label regimen. The concomitant administration of high loading dose clopidogrel, by bridging with abciximab bolus, may sustain suppression of platelet activity over time.lld:pubmed
pubmed-article:20586923pubmed:languageenglld:pubmed
pubmed-article:20586923pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20586923pubmed:citationSubsetIMlld:pubmed
pubmed-article:20586923pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20586923pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20586923pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20586923pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20586923pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20586923pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20586923pubmed:statusMEDLINElld:pubmed
pubmed-article:20586923pubmed:monthSeplld:pubmed
pubmed-article:20586923pubmed:issn1538-7836lld:pubmed
pubmed-article:20586923pubmed:authorpubmed-author:MontiMMlld:pubmed
pubmed-article:20586923pubmed:authorpubmed-author:FerraroTTlld:pubmed
pubmed-article:20586923pubmed:authorpubmed-author:CampoGGlld:pubmed
pubmed-article:20586923pubmed:authorpubmed-author:ScalonaMMlld:pubmed
pubmed-article:20586923pubmed:authorpubmed-author:ParrinelloGGlld:pubmed
pubmed-article:20586923pubmed:authorpubmed-author:TebaldiMMlld:pubmed
pubmed-article:20586923pubmed:authorpubmed-author:ValgimigliMMlld:pubmed
pubmed-article:20586923pubmed:authorpubmed-author:GambettiSSlld:pubmed
pubmed-article:20586923pubmed:authorpubmed-author:Fabolus...lld:pubmed
pubmed-article:20586923pubmed:copyrightInfo© 2010 International Society on Thrombosis and Haemostasis.lld:pubmed
pubmed-article:20586923pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20586923pubmed:volume8lld:pubmed
pubmed-article:20586923pubmed:ownerNLMlld:pubmed
pubmed-article:20586923pubmed:authorsCompleteYlld:pubmed
pubmed-article:20586923pubmed:pagination1903-11lld:pubmed
pubmed-article:20586923pubmed:meshHeadingpubmed-meshheading:20586923...lld:pubmed
pubmed-article:20586923pubmed:meshHeadingpubmed-meshheading:20586923...lld:pubmed
pubmed-article:20586923pubmed:meshHeadingpubmed-meshheading:20586923...lld:pubmed
pubmed-article:20586923pubmed:meshHeadingpubmed-meshheading:20586923...lld:pubmed
pubmed-article:20586923pubmed:meshHeadingpubmed-meshheading:20586923...lld:pubmed
pubmed-article:20586923pubmed:meshHeadingpubmed-meshheading:20586923...lld:pubmed
pubmed-article:20586923pubmed:meshHeadingpubmed-meshheading:20586923...lld:pubmed
pubmed-article:20586923pubmed:meshHeadingpubmed-meshheading:20586923...lld:pubmed
pubmed-article:20586923pubmed:meshHeadingpubmed-meshheading:20586923...lld:pubmed
pubmed-article:20586923pubmed:meshHeadingpubmed-meshheading:20586923...lld:pubmed
pubmed-article:20586923pubmed:meshHeadingpubmed-meshheading:20586923...lld:pubmed
pubmed-article:20586923pubmed:meshHeadingpubmed-meshheading:20586923...lld:pubmed
pubmed-article:20586923pubmed:meshHeadingpubmed-meshheading:20586923...lld:pubmed
pubmed-article:20586923pubmed:meshHeadingpubmed-meshheading:20586923...lld:pubmed
pubmed-article:20586923pubmed:meshHeadingpubmed-meshheading:20586923...lld:pubmed
pubmed-article:20586923pubmed:meshHeadingpubmed-meshheading:20586923...lld:pubmed
pubmed-article:20586923pubmed:meshHeadingpubmed-meshheading:20586923...lld:pubmed
pubmed-article:20586923pubmed:year2010lld:pubmed
pubmed-article:20586923pubmed:articleTitleRandomized, double-blind comparison of effects of abiciximab bolus only vs. on-label regimen on ex vivo inhibition of platelet aggregation in responders to clopidogrel undergoing coronary stenting.lld:pubmed
pubmed-article:20586923pubmed:affiliationInstitute of Cardiology, University of Ferrara, Ferrara, Italy. vlgmrc@unife.itlld:pubmed
pubmed-article:20586923pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:20586923pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:20586923pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed